Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 4Thoracic 3Genitourinary 3Gynecologic 2Gastrointestinal 2Sarcoma 1Other solid neoplasm 1Head & Neck 1Dermatologic 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Advanced Malignant Solid Neoplasm 1

Interventions

pembrolizumab 6Nivolumab 3budigalimab 2Paclitaxel 2Ipilimumab 2Docetaxel 2venetoclax 1tislelizumab 1talazoparib 1spartalizumab 1rovalpituzumab tesirine 1regorafenib 1obinutuzumab 1naptumomab estafenatox 1fludarabine 1epacadostat 1durvalumab 1cabozantinib 1Platinum 1Levoleucovorin 1Leucovorin 1Interleukin-2 1IPI-549 1Gemcitabine 1Fluorodeoxyglucose F18 1Everolimus 1Cyclophosphamide 1Clinical Trials, Phase II as Topic 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × cabozantinib × Other solid neoplasm × Clear all
NCT02071862 2022-07-20

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Calithera Biosciences, Inc

Phase 1 Completed
210 enrolled
BreastGenitourinaryOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Mesothelioma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡